MedTrace Logo

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)

NCT02471118 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-10-27

No results posted yet for this study

Summary

This is a Canadian randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the clinical efficacy and safety of adalimumab versus placebo when used to treat subjects with a diagnosis of osteoarthritis of the knee, and with clinical features of inflammation, whose pain persists despite receiving maximum tolerated doses of conventional therapy.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Adalimumab 40 mg

Adalimumab will be self-administered via subcutaneous (SC) injection

DRUG

Placebo

Placebo will be self-administered via subcutaneous (SC) injection

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • CARE ARTHRITIS LTD.

    lead INDUSTRY

Principal Investigators

  • Dr. Walter P Maksymowych, MD, FRCPC · CARE ARTHRITIS LTD.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471118 on ClinicalTrials.gov